'Liver Ca may also be a success, but surely there would need to be large trials against established therapies before Oncosil could break into this market.'
Yes, as SRX have found these phase 3 trails can take years. The real challenge in a trial is that should SRX, and that is currently an unknown, get some good results from the HCC trials already completed, then any new treatment for HCC may have to go head to head with SRX.
I think pancreatic Ca would be the immediate aim, as it is a very aggressive Ca, with few treatment options.
As an aside - Van-leewenhoeck - who are these dudes? Never heard of them before. Why would NY based research house even look at OSL, out of the thousands of up and coming companies in the world in the medical space?
Are there commercial arrangements of any description ?
OSL Price at posting:
18.0¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)